ChemicalBook
English   Japanese   Germany   Korea

(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺

(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺, 1004990-28-6, 结构式
(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺
CAS号:
1004990-28-6
英文名:
N-[[(3S)-3-AMINO-1-(5-ETHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3-PYRROLIDINYL]METHYL]-2,4-DIFLUORO-BENZAMIDE
英文别名:
PF-AKT400;AKT inhibitor (AKT protein kinase inhibitor);Protein kinase B,PF-AKT400,Akt,inhibit,PKB,PF-AKT-400,PF AKT400,Inhibitor,PFAKT400;(S)-N-[[3-Amino-1-(5-ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-3-yl]methyl]-2,4-difluorobenzamide;N-[[(3S)-3-AMINO-1-(5-ETHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3-PYRROLIDINYL]METHYL]-2,4-DIFLUORO-BENZAMIDE;BenzaMide, N-[[(3S)-3-aMino-1-(5-ethyl-7H-pyrrolo[2,3-d]pyriMidin-4-yl)-3-pyrrolidinyl]Methyl]-2,4-difluoro-
中文名:
(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺
中文别名:
化合物PF-AKT400;AKT抑制剂(PF-AKT400);(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺
CBNumber:
CB82465575
分子式:
C20H22F2N6O
分子量:
400.43
MOL File:
1004990-28-6.mol

(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺化学性质

密度:
1.353
储存条件:
Store at -20°C
溶解度:
DMSO : ≥ 100 mg/mL (249.73 mM)
安全信息

(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺性质、用途与生产工艺

生物活性

PF-AKT400 是一种有效的, ATP 竞争性的选择性 Akt 抑制剂,对 PKBα (IC50=0.5 nM) 的选择性比 PKA (IC50=450 nM) 高 900 倍。

靶点

PKBα

0.5 nM (IC 50 )

PKA

450 nM (IC 50 )

体外研究

PF-AKT400 (Compound 42) provides significantly enhanced selectivity for Akt relative to earlier leads such as spiroindoline 2. Free IC 50 and EC 50 values are estimated for phospho-S6 reduction (110 nM) and Akt hyperphosphorylation (216 nM), respectively. These values corresponded well to the cellular IC 50 for PF-AKT400 in U87 cells measuring p-GSK-3α (310 nM).

体内研究

PF-AKT400 is subsequently evaluated for modulation of Akt in tumors and in multiple in vivo mouse models of antitumor efficacy. It is active in a PC3 prostate carcinoma xenograft experiment, with 75% TGI observed at 100 mg/kg b.i.d. dosing for 10 days. In a colorectal carcinoma (Colo205) xenograft study, PF-AKT400 produces 60% TGI at 150 mg/kg b.i.d. after 10 days. Most intriguingly, in combination with Rapamycin (10 mg/kg, ip), 75 mg/kg b.i.d. (10 days) of PF-AKT400 results in 98% TGI in an additional PC3 prostate carcinoma xenograft study compared to 56% TGI and 66% TGI with PF-AKT400 and Rapamycin as single agents. To define the in vivo potency of PF-AKT400 (Compound 42) in the PC3 xenograft model, oral administration of 25, 75, and 100 mg/kg PF-AKT400 is performed with blood and tumor sampling over time. Immunoblot analysis of detergent-soluble extracts derived from PC3 tumors shows a significant reduction of S6 phosphorylation, and hyperphosphorylation of Akt upon treatment at doses that produced significant tumor growth inhibition. Plasma drug concentrations peak rapidly after oral administration of doses between 25-100 mg/kg (T max =0.5 h). Peak PD responses of phospho-S6 and phospho-Akt are observed at approximately 2-4h and 1h post-administration of PF-AKT400, respectively. The time-course of PD marker response is well described by a PK/PD model at doses that ranged from no efficacy (25 mg/kg) to maximal efficacy (100 mg/kg).

(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺 上下游产品信息

上游原料

下游产品

(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺 试剂级价格

更新日期产品编号产品名称CAS编号包装价格
2024/04/30HY-10721PF-AKT4001 mg1160元
2024/04/30HY-10721(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺
PF-AKT400
1004990-28-65mg2900元

(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺 生产厂家

供应商联系电话电子邮件国家产品数优势度
南京诺利斯医药科技有限公司 13901585132 799750417@qq.com 中国 8888 55
上海皓元医药股份有限公司 021-58950125 info@chemexpress.com 中国 7553 61
上海陶素生化科技有限公司 021-33632979 info@tsbiochem.com 中国 8073 58
四川省维克奇生物科技有限公司 028-81700200 18116577057 3003855609@qq.com 中国 7892 56
上海昶衍化工科技有限公司 021-021-20242659 18930833303 order@changyanchem.com 中国 5008 55
上海瀚香生物科技有限公司 17754423994 17754423994 2853530910@QQ.com 中国 8011 62
德州博腾精细化工有限公司 13006575422@163.com 中国 6357 58
北京索莱宝科技有限公司 010-50973130 4009686088 3193328036@qq.com 中国 29796 68
Musechem +1-800-259-7612 info@musechem.com 美国 4662 60
深圳市丽晶生化科技有限公司 0755-0755-85201366 18938635012 sales@regentsciences.com 中国 9293 58
InvivoChem +1-708-310-1919 +1-13798911105 sales@invivochem.cn 美国 6393 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD 86-571-88216897,88216896 13588875226 sales@hzclap.com 中国 6313 58
上海源溪生物科技有限公司 021-58447131 13564518121 sales@dcchemicals.com 中国 9414 58
常州辰鸿生物科技有限公司 0519-85788828 13775037613 sales@chemrenpharm.com 中国 3574 58
济南思考化学有限公司 0531-0000 thinklifescience@163.com 中国 19690 58
ChemeGen 中国 18818260767 sales@chemegen.com 中国 11289 58
重庆卡兰医药有限公司 +8618523575427 sales@conier.com 中国 49391 58
上海泽叶生物科技有限公司 021-61998551 13122364865 sale1@shzysw.net 中国 9771 58
爱必信(上海)生物科技有限公司 021-38015121 15000105423 chenjw@absin.cn 中国 24734 58
上海弘渠生物医药科技有限公司 88888888888 hongquchem@qq.com 中国 5132 58
上海博拓生物科技有限公司 16621358918 botuopharma888@163.com 中国 9215 58
安耐吉化学&3A(安徽泽升科技有限公司) 021-58432009 400-005-6266 marketing1@energy-chemical.com 中国 44843 58
天津普西唐生物医药科技有限公司 010-60605840 psaitong@jm-bio.com 中国 29778 58
开封明仁药业有限公司 0371-65741762 sales@hasunny.com 中国 2380 58
InvivoChem中国 13549236410 sales@invivochem.cn 中国 6749 58
南京诺利斯医药科技有限公司 13901585132 2261760024@qq.com 中国 4908 58
TargetMol中国(陶术生物) 4008200310 marketing@tsbiochem.com 中国 24018 58
南京世洲生物科技有限公司 025-85560043 15850508050 cindy.huang@synzest.com 中国 12007 58
銳迪國際科技有限公司 18024082417 market@ubiochem.com 中国 9180 58
Shanghai Acmec Biochemical Technology Co., Ltd. +undefined18621343501 product@acmec-e.com 中国 33350 58
TargetMol Chemicals Inc. +1-781-999-5354 support@targetmol.com 美国 19973 58
 

1004990-28-6, (S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺 相关搜索:

  • Amines, Aromatics, Chiral Reagents, Heterocycles, Protein Kinase Inhibitors and Activators, Pharmaceuticals, Intermediates & Fine Chemicals
  • Protein Kinase Inhibitors and Activators
  • Pharmaceuticals
  • Intermediates & Fine Chemicals
  • Heterocycles
  • Chiral Reagents
  • Aromatics
  • Amines
  • 中药对照品
  • 细胞生物学试剂
  • C20H22F2N6O
  • 化合物PF-AKT400
  • AKT抑制剂(PF-AKT400)
  • (S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺
  • 1004990-28-6
  • Protein kinase B,PF-AKT400,Akt,inhibit,PKB,PF-AKT-400,PF AKT400,Inhibitor,PFAKT400
  • AKT inhibitor (AKT protein kinase inhibitor)
  • PF-AKT400
  • BenzaMide, N-[[(3S)-3-aMino-1-(5-ethyl-7H-pyrrolo[2,3-d]pyriMidin-4-yl)-3-pyrrolidinyl]Methyl]-2,4-difluoro-
  • (S)-N-[[3-Amino-1-(5-ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-3-yl]methyl]-2,4-difluorobenzamide
  • N-[[(3S)-3-AMINO-1-(5-ETHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3-PYRROLIDINYL]METHYL]-2,4-DIFLUORO-BENZAMIDE
Copyright 2016 © ChemicalBook. All rights reserved